{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T08:29:10Z","timestamp":1782203350841,"version":"3.54.5"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Analytical methods require performance that meets the clinical needs. Different approaches for setting up permissible analytical imprecision goals (pCVA%) for drug analyses have been reported. The aim of this study was to calculate the pCV<jats:sub>A<\/jats:sub>% for cyclosporine, tacrolimus, everolimus, sirolimus, and mycophenolic acid using 4 alternative approaches, to compare the results and to critically discuss advantages and disadvantages of each model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The approaches to evaluate pCV<jats:sub>A<\/jats:sub>% were (A) based on biological variation observed in routine measurement results between 2022 and 2023 in the authors' laboratory, (B) derived from the terminal elimination half-life and dosing interval of the drugs, and (C and D) explored from the width of the therapeutic ranges (TR) by the 2 methods. For approach A, routine measurement data for cyclosporine and tacrolimus, obtained through liquid chromatography\u2013tandem mass spectrometry and electrochemiluminescence immunoassays, were evaluated separately.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The 4 alternative approaches for deriving pCV<jats:sub>A<\/jats:sub>% yielded similar results, for cyclosporine and tacrolimus in an analytical method dependent manner. The average pCV<jats:sub>A<\/jats:sub>% was 5.2%, 5.6%, 5.1%, 4.8%, and 7.7% for cyclosporine, tacrolimus, everolimus, sirolimus, and mycophenolic acid, respectively. The most challenging goals were those using TR-related approaches, while those using the biological variation approach were most easily achievable. Approach B resulted in more stringent goals for drugs with longer elimination half-lives (eg, everolimus and sirolimus).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>There is no single ideal approach for setting goals of drug analysis. However, the pCV<jats:sub>A<\/jats:sub>% values derived from the various approaches are similar and confirm that a &lt;6% target proposed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology is adequate and realistic in combination with state-of-the-art measurement technologies. In the authors' opinion, approaches based on the width of the TR are preferable, as they represent a common basis for clinical decisions and reflect elements of biological variation and analytics used to establish the TR.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001261","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T21:00:07Z","timestamp":1727902807000},"page":"32-40","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Toward Analytical Performance Specifications for Immunosuppressive Drug Quantification in Transplantation: An Opinion Article"],"prefix":"10.1097","volume":"47","author":[{"given":"Maria","family":"Shipkova","sequence":"first","affiliation":[{"name":"Bioscientia Institut f\u00fcr Medizinische Diagnostik, Ingelheim, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eberhard","family":"Wieland","sequence":"additional","affiliation":[{"name":"Bioscientia Institut f\u00fcr Medizinische Diagnostik, Ingelheim, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekkerhard","family":"Sch\u00fctz","sequence":"additional","affiliation":[{"name":"Oncocyte Corporation, Nashville, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,2]]},"reference":[{"key":"R1-20250108","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/FTD.0000000000000269","article-title":"Assuring the proper analytical performance of measurement procedures for immunosuppressive drug concentrations in clinical practice: recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology immunosuppressive drug scientific committee","volume":"38","author":"Seger","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R2-20250108","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/FTD.0000000000000205","article-title":"Impact of laboratory practices on interlaboratory variability in therapeutic drug monitoring of immunosuppressive drugs","volume":"37","author":"Christians","year":"2015","journal-title":"Ther Drug Monit."},{"key":"R3-20250108","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/clinchem\/33.3.387","article-title":"Desirable standards of performance for therapeutic drug monitoring","volume":"33","author":"Fraser","year":"1987","journal-title":"Clin Chem."},{"issue":"pt 3","key":"R4-20250108","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1177\/000456328902600302","article-title":"Desirable performance standards for assays of drugs","volume":"26","author":"Stewart","year":"1989","journal-title":"Ann Clin Biochem."},{"key":"R5-20250108","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/clinchem\/22.4.475","article-title":"Expression of random analytical error as a percentage of the range of clinical interest","volume":"22","author":"Glick","year":"1976","journal-title":"Clin Chem."},{"key":"R7-20250108","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1373\/clinchem.2013.217125","article-title":"Practice-oriented quality specifications for therapeutic drug monitoring","volume":"60","author":"Pauwels","year":"2014","journal-title":"Clin Chem."},{"key":"R8-20250108","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.pathol.2018.12.418","article-title":"Indirect derivation of biological variation data and analytical performance specifications for therapeutic drug monitoring activities","volume":"51","author":"Chai","year":"2019","journal-title":"Pathology"},{"issue":"2 suppl","key":"R9-20250108","first-page":"374","article-title":"Statistical principles underlying analytic goal-setting in clinical chemistry","volume":"72","author":"Harris","year":"1979","journal-title":"Am J Clin Pathol."},{"key":"R10-20250108","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1515\/cclm-2015-0067","article-title":"Defining analytical performance specifications: consensus statement from the 1st strategic conference of the European federation of clinical chemistry and laboratory medicine","volume":"53","author":"Sandberg","year":"2015","journal-title":"Clin Chem Lab Med."},{"key":"R11-20250108","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1515\/cclm-2022-0806","article-title":"Definition and application of performance specifications for measurement uncertainty of 23 common laboratory tests: linking theory to daily practice","volume":"61","author":"Braga","year":"2023","journal-title":"Clin Chem Lab Med."},{"key":"R12-20250108","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1515\/cclm-2023-1063","article-title":"Analytical performance specifications for measurement uncertainty in therapeutic monitoring of immunosuppressive drugs","volume":"62","author":"Cattaneo","year":"2024","journal-title":"Clin Chem Lab Med."},{"key":"R13-20250108","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1515\/CCLM.2011.116","article-title":"A new concept to derive permissible limits for analytical imprecision and bias considering diagnostic requirements and technical state-of-the-art","volume":"49","author":"Haeckel","year":"2011","journal-title":"Clin Chem Lab Med."},{"key":"R14-20250108","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1515\/cclm-2014-0874","article-title":"Permissible limits for uncertainty of measurement in laboratory medicine","volume":"53","author":"Haeckel","year":"2015","journal-title":"Clin Chem Lab Med."},{"key":"R15-20250108","doi-asserted-by":"crossref","first-page":"729","DOI":"10.5858\/2001-125-0729-AEOAGF","article-title":"An evaluation of analytic goals for assays of drugs: a College of American Pathologists therapeutic drug monitoring survey study","volume":"125","author":"Steele","year":"2001","journal-title":"Arch Pathol Lab Med."},{"key":"R16-20250108","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/biomet\/52.3-4.591","article-title":"An analysis of variance test for normality (complete samples)","volume":"52","author":"Shapiro","year":"1965","journal-title":"Biometrika"},{"key":"R18-20250108","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.clinbiochem.2019.11.006","article-title":"An isotope dilution LC-MS\/MS based candidate reference method for the quantification of cyclosporine A, tacrolimus, sirolimus and everolimus in human whole blood","volume":"82","author":"Taibon","year":"2020","journal-title":"Clin Biochem."},{"key":"R19-20250108","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/00365513.2020.1731849","article-title":"Using ISO\/TS 20914: 2019 to calculate the measurement uncertainty of immunosuppressive drugs in a clinical laboratory","volume":"80","author":"Grote-Koska","year":"2020","journal-title":"Scand J Clin Lab Invest."},{"key":"R21-20250108","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2165\/00003088-200140040-00004","article-title":"Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients","volume":"40","author":"Wallemacq","year":"2001","journal-title":"Clin Pharmacokinet."},{"key":"R22-20250108","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/ajt.13111","article-title":"Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir","volume":"15","author":"Badri","year":"2015","journal-title":"Am J Transpl."},{"key":"R23-20250108","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1208\/s12248-013-9500-8","article-title":"Population pharmacokinetics of cyclosporine in transplant recipients","volume":"15","author":"Han","year":"2013","journal-title":"AAPS J."},{"key":"R24-20250108","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0009-9236(01)15633-X","article-title":"Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment","volume":"70","author":"Kovarik","year":"2001","journal-title":"Clin Pharmacol Ther."},{"key":"R25-20250108","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1517\/14740338.2015.1040388","article-title":"Everolimus and sirolimus in transplantation-related but different","volume":"14","author":"Klawitter","year":"2015","journal-title":"Expert Opin Drug Saf."},{"key":"R26-20250108","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1399-3046.2003.00148.x","article-title":"Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol","volume":"8","author":"Schachter","year":"2004","journal-title":"Pediatr Transpl."},{"key":"R27-20250108","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-200746010-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients","volume":"46","author":"Staatz","year":"2007","journal-title":"Clin Pharmacokinet."},{"key":"R28-20250108","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/lt.21146","article-title":"Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil","volume":"13","author":"Jain","year":"2007","journal-title":"Liver Transpl."},{"key":"R29-20250108","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/bcp.13838","article-title":"A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients","volume":"85","author":"Andrews","year":"2019","journal-title":"Br J Clin Pharmacol."},{"key":"R30-20250108","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40262-013-0037-x","article-title":"Ciclosporin population pharmacokinetics and Bayesian estimation in thoracic transplant recipients","volume":"52","author":"Fruit","year":"2013","journal-title":"Clin Pharmacokinet."},{"key":"R31-20250108","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/11599710-000000000-00000","article-title":"Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients","volume":"51","author":"Moes","year":"2012","journal-title":"Clin Pharmacokinet."},{"key":"R32-20250108","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00003088-200645110-00007","article-title":"Sirolimus population pharmacokinetic\/pharmacogenetic analysis and Bayesian modelling in kidney transplant recipients","volume":"45","author":"Djebli","year":"2006","journal-title":"Clin Pharmacokinet."},{"key":"R33-20250108","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2165\/00003088-200544100-00006","article-title":"Population pharmacokinetics of mycophenolic acid in renal transplant recipients","volume":"44","author":"van Hest","year":"2005","journal-title":"Clin Pharmacokinet."},{"key":"R34-20250108","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","article-title":"Personalized therapy for mycophenolate: consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology","volume":"43","author":"Bergan","year":"2021","journal-title":"Ther Drug Monit."},{"key":"R35-20250108","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R36-20250108","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/FTD.0000000000001250","article-title":"Everolimus personalized therapy: second consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology","volume":"47","author":"Masuda","year":"2025","journal-title":"Ther Drug Monit"},{"key":"R37-20250108","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/clinchem\/48.3.517","article-title":"Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy","volume":"48","author":"Weber","year":"2002","journal-title":"Clin Chem."},{"key":"R38-20250108","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/FTD.0000000000000376","article-title":"Therapeutic drug monitoring of everolimus: comparability of concentrations determined by 2 immunoassays and a liquid chromatography tandem mass spectrometry method","volume":"39","author":"Shipkova","year":"2017","journal-title":"Ther Drug Monit."},{"key":"R39-20250108","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1515\/cclm-2020-0848","article-title":"Evaluation of the first immunosuppressive drug assay available on a fully automated LC-MS\/MS-based clinical analyzer suggests a new era in laboratory medicine","volume":"59","author":"H\u00f6rber","year":"2021","journal-title":"Clin Chem Lab Med."},{"key":"R40-20250108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jmsacl.2023.07.001","article-title":"Automated LC-MS\/MS: ready for the clinical routine laboratory?","volume":"30","author":"Junger","year":"2023","journal-title":"J Mass Spectrom Adv Clin Lab."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001261","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T15:01:15Z","timestamp":1736348475000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,2]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001261","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,2]]},"assertion":[{"value":"2024-06-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}